AstraZeneca Lags in Cancer Race Where Losing May Spur Buyout
This article is for subscribers only.
Working to fend off a takeover last May, AstraZeneca Plc told investors it could raise its revenue 75 percent by 2023, thanks in part to a robust pipeline of experimental drugs.
Almost a year later, those projections look shaky as rivals are moving ahead of the company in immune therapies for cancer, one of the hottest areas of drug development.